https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/bioworld-logo-vector.jpg8431500Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:01:562026-08-14 16:11:45NRG closes £16M series A to fund fight against neurodegenerative diseases
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/BusinessWeekly_NRG.jpg8191238Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-11-09 08:00:562026-08-14 16:12:46GSK vets theorize that a mitochondrial target may unlock Parkinson’s and ALS treatments in new startup
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/bioworld-logo-vector.jpg8431500Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-08-31 08:00:422026-09-09 17:40:56NRG gearing up for series A to advance brain-penetrant PTP inhibitors
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/QW04Z4YLERS41E7A85IO.jpg437750Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-07-07 08:00:252026-08-14 16:20:20NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/shutterstock-mitochondria.jpg6831024Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-06-30 08:00:392026-08-14 16:22:31NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/chronic-neurodegenerative-disorders.jpg450750Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-06-24 08:00:052026-09-10 10:29:34NRG Therapeutics to develop small molecule disease-modifying medicines for debilitating chronic neurodegenerative disorders
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Change-Jars.jpg461700Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-06-01 08:00:202026-08-14 16:27:17£2.68M Award to NRG Therapeutics Supports Work Into Potential DMT
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/shutterstock_664712080.jpg6831024Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-05-31 08:00:272026-08-14 16:28:13Award to help NRG Therapeutics develop new Parkinson’s and Motor Neurone Disease treatments
https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/methode_sundaytimes.jpg450800Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2022-05-29 08:00:262026-09-09 17:41:02Sticking plaster for brain could beat Parkinson’s disease
NRG closes £16M series A to fund fight against neurodegenerative diseases
Bioworld
Read more
GSK vets theorize that a mitochondrial target may unlock Parkinson’s and ALS treatments in new startup
Endpoints
Read more
NRG gearing up for series A to advance brain-penetrant PTP inhibitors
Bioworld
Read more
(behind a paywall)
NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease
Cambridge Independent
Read more
NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
PMLive
Read more
NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders
Labiotech
Read more
NRG Therapeutics to develop small molecule disease-modifying medicines for debilitating chronic neurodegenerative disorders
Drug Target Review
£2.68M Award to NRG Therapeutics Supports Work Into Potential DMT
Parkinson’s News Today
Read more
Award to help NRG Therapeutics develop new Parkinson’s and Motor Neurone Disease treatments
Labiotech
Read more
NRG receives £2.68m funding boost for neurodegenerative disorders
Pharma Times
Read more
Sticking plaster for brain could beat Parkinson’s disease
Sunday Times
Read more
(behind a paywall)
NRG Therapeutics awarded £2.68m to fight Parkinson’s and MND
Business Weekly
Read more